No Data
Express News | Huakang Biomedical Holdings - He Jiaming Resigns as an Executive Director
Express News | Huakang Biomedical - Zhang Yujing Appointed as Executive Director
HUAKANG BIOMED: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Express News | Huakang Biomedical - Co to Acquire 51% Equity Interest in Hunan Keyue Biotechnology
HUAKANG BIOMED (08622.HK): Xu Yongde was appointed as an independent director.
On January 22, Glonghui reported that HUAKANG BIOMED (08622.HK) announced that the Board of Directors will implement the following changes effective from January 22, 2025: (1) Zhou Jingwen has resigned as the company's independent non-executive director and will no longer serve as a member of the company's audit committee and nomination committee; and (2) Xu Yongde has been appointed as the company's independent director, as well as a member of the audit committee and nomination committee.
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of Holding
